Clinical Trials

Inclusion Criteria:

• Female (legal, identity, or sex assigned at birth) patients.
• Ages 18 to 99 years.
• Patient is an established Mayo Clinic Florida, Department of Family Medicine patient. Within past 3 years the patient has had an encounter with the Family Medicine Practice.
• Patient reports new onset urinary frequency or urgency or pain with urination.

Exclusion Criteria:

• Patient reports trauma to abdomen within 24 hours of onset of urinary symptoms.
• Patient has pain rated 8-10 out of 10.
• Patient reports pregnancy confirmed by lab, ultrasound, or home pregnancy test.
• Patient resides in a nursing home currently or was discharged from a long-term care facility in the last 2 weeks.
• Patient has baseline cognitive impairment (e.g., dementia, Alzheimer’s).

Exclusion Criteria (AI): 

• Patient reports shaking chills, any flank pain, nausea, or vomiting.
• Patient reports temperature of 100.4 F or more.
• Patient reports compromised immune system (examples include having HIV/AIDS or sickle cell disease, receiving chemotherapy or radiation, taking prednisone 20 mg daily or more, or immunosuppressive medication.
• Duration of urinary symptoms has been 7 days or more.
• Patient has a documented kidney infection in the past 3 months, reports history of kidney stones in the past 12 months, history of renal transplant or reports decreased kidney function, or patient’s most recent serum (blood) Creatinine is 1.5 mg/dL or more or eGFR 60mL/minute or less.
• Patient reports receiving antibiotics for UTI within the past 4 weeks or has 3 or more documented UTIs within the past 12 months.
• Patient has recent onset of, or change in vaginal discharge, odor, itching or painful intercourse.
• Patient has been discharged from the hospital within the last 30 days.
• Patient reports a urinary procedure, surgical procedure, or urinary catheterization within the past 30 days.
• Patient reports history of diabetes mellitus or is taking Warfarin or Direct Oral Anticoagulant medication (DOACs include but not limited to Apixaban, Dabigatran, Edoxaban, Rivaroxaban).

Eligibility last updated 11/2/22. Questions regarding updates should be directed to the study team contact.